You are here

SARC002

Completed
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Type of Sarcoma: 
Unresectable soft tissue sarcoma
Drug: 
Gemcitabine and Docetaxel
Accrual Status: 
Completed
Overall Study Principal Investigator: 

Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

For more information about this trial and open sites: